摩根士丹利近日发布研报，针对减肥药领域近期动态发表点评。信诺 (CI.US)旗下Evernorth最近宣布了一项新的福利方案，将患者每月使用礼来 (LLY.US)Zepbound和诺和诺德 (NVO.US)Wegovy的自付费用上限设定为200美元，并维持其非排他性策略。

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth division announced that it would cap out-of-pocket costs at $200 per month ...

Investing.com — Hims & Hers Health, Inc. (NYSE: HIMS)，一家领先的健康与保健平台，宣布为处方肥胖治疗药物Wegovy®推出新的定价选择。从今天开始，在Hims & Hers平台上符合Wegovy®资格的新客户可以以每月549美元的价格开始为期六个月的治疗。这一优惠仅在限定时间内提供，旨在让数百万美国人更容易负担肥胖治疗费用。 该公司首席执行官兼联 ...

减肥药制造商诺和诺德周三自四年前推出减肥药 Wegovy 以来首次下调销售预期，但该公司股价盘前上涨7.8%，原因是该公司预计其最大市场美国的销售 ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced Wednesday ...

New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says. Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock ...